Last Update 07 Aug 26
Fair value Increased 13%PACS: Raised 2026 Guidance And Eduro Expansion Will Drive Repricing Potential
Analysts increased their fair value estimate for PACS Group to $59.75 from $52.67, pointing to refreshed models that incorporate updated revenue growth assumptions, a slightly higher discount rate, a modestly lower profit margin outlook, and higher future P/E expectations. These expectations are broadly in line with recent price target moves toward $60.
Analyst Commentary
Recent research on PACS Group centers on a series of price target adjustments that cluster around the US$48 to US$60 range. These moves focus on how the company is executing on its guidance, particularly following Q1 results and updated 2026 expectations, and how that flows through to valuation and P/E assumptions.
Bullish Takeaways
- Bullish analysts have stepped price targets up in stages from US$42 to US$60 over the course of multiple updates, which signals growing confidence in how PACS Group is tracking against its own outlook.
- Several price target increases follow earnings updates and refreshed guidance through 2026. This suggests that model revisions are grounded in reported results rather than purely theoretical long term assumptions.
- One research note described the quarter as really impressive and highlighted that PACS Group is regaining traction with the Street. This points to improving sentiment on both execution and growth visibility.
- Higher target prices align with expectations for a stronger future P/E profile. This indicates that some analysts see room for the stock to support a richer valuation if the company delivers on its plan.
Bearish Takeaways
- Despite the higher targets, recent moves cluster tightly around US$57 to US$60. This may imply that bullish analysts see less room for substantial upside beyond this band without further evidence of outperformance.
- Target changes are tied to updates after specific quarters and guidance revisions, so any miss against those expectations could lead to swift changes in sentiment and revised models that reduce valuation support.
- The focus on higher future P/E assumptions introduces sensitivity to market appetite for PACS Group at those multiples. This can create downside risk if investors later demand a lower P/E for the same earnings profile.
- Positive commentary around PACS Group regaining Street traction also hints that prior sentiment was more cautious, which is a reminder that support from research can shift if company execution or communication weakens.
What’s in the News for PACS Group
- PACS Group, Inc. reported second quarter 2026 results with revenue up 9.1% and net income up 49.8% year over year, and raised full year 2026 adjusted EBITDA and revenue guidance. Source: PACS Group, Inc. Reports Second Quarter 2026 Results.
- The company is expanding through acquisitions and closed on 20 Texas skilled nursing facilities from Eduro Healthcare, with additional facilities expected to close later in 2026. Source: PACS Group, Inc. Reports Second Quarter 2026 Results.
- PACS Group increased its 2026 revenue guidance range to US$5.75b to US$5.85b, up from the prior range of US$5.65b to US$5.75b.
- The company announced a share repurchase program authorizing buybacks of up to US$250m of its shares, with no fixed expiration date.
- PACS Group was removed from several Russell value indexes in 2026, including the Russell 2000 Value, Russell 3000 Value, Russell Small Cap Comp Value, Russell 2500 Value and Russell 3000E Value benchmarks.
Valuation Changes for PACS Group
- Fair Value has risen from $52.67 to $59.75, which is an increase of about 13% in the updated PACS Group model.
- Discount Rate has moved slightly higher from 7.39% to 7.50%, suggesting a modestly higher hurdle rate in the revised assumptions.
- Revenue Growth has risen from 7.40% to 8.88%, indicating higher expected top line expansion for PACS Group in the latest forecast.
- Net Profit Margin has edged lower from 6.94% to 6.44%, which reflects slightly more cautious profitability assumptions.
- Future P/E has increased from 22.76x to 26.21x, pointing to a higher valuation multiple being used for PACS Group in the updated work.
Catalysts
About PACS Group
PACS Group operates a large, locally led, centrally supported network of skilled nursing and post-acute care facilities across the United States.
What are the underlying business or industry changes driving this perspective?
- Rising demand for post-acute and long-term care from an aging U.S. population, combined with PACS Group's expanding footprint of over 35,000 beds, creates room for continued top line growth as occupancy and patient volumes increase, supporting higher revenue and earnings.
- Systematic improvement of newly acquired and turnaround facilities from low single digit margins toward the high single digit and low double digit margin profile of mature sites should unlock embedded profitability, lifting consolidated net margins and EBITDA over time.
- Strengthening Medicaid and quality incentive frameworks in targeted states, where higher acuity and quality outcomes are rewarded, align with PACS Group's clinically driven model, which can translate into better reimbursement per patient and sustained growth in revenue and operating income.
- Enhanced internal controls, compliance infrastructure and governance following the audit committee process reduce perceived risk and cost of capital, which can support more efficient capital allocation, higher free cash flow conversion and ultimately stronger earnings per share.
- A robust pipeline of internally developed administrators and leaders through the AIT program supports scalable execution as the industry consolidates, enabling disciplined M&A at attractive valuations that is accretive to adjusted EBITDA and long-term earnings growth.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming PACS Group's revenue will grow by 8.9% annually over the next 3 years.
- Analysts assume that profit margins will increase from 4.8% today to 6.4% in 3 years time.
- Analysts expect earnings to reach $461.5 million (and earnings per share of $2.52) by about August 2029, up from $269.2 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.3x on those 2029 earnings, down from 27.5x today. This future PE is greater than the current PE for the US Healthcare industry at 25.8x.
- Analysts expect the number of shares outstanding to grow by 1.1% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.5%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- The rapid portfolio expansion in 2024, where over 100 facilities were acquired and roughly one third of the portfolio now sits in new or ramping cohorts with lower occupancy and margins, may stretch management capacity and delay operational turnarounds. This could limit future revenue growth and compress net margins if integration takes longer or costs more than expected.
- The business model depends heavily on favorable Medicaid structures, quality incentive programs, and case mix reimbursement in key states such as California, Washington, Texas, Kentucky, and Ohio. Any adverse policy or rate changes in these mature and growth markets could reduce reimbursement per patient and slow earnings and EBITDA growth despite solid clinical outcomes.
- Occupancy strength is concentrated in mature facilities at 95 percent, while new facilities operate at roughly 81 percent with weaker skilled mix. If hospital discharge patterns, competitive dynamics, or local referral relationships shift unfavorably, the company may struggle to lift newer cohorts to mature performance levels, which could constrain top line growth and limit margin expansion.
- The company only recently completed an audit committee investigation, restatement, and internal control remediation following a short seller report. If any remaining control weaknesses, governance lapses, or new compliance issues emerge, they could increase regulatory and legal costs, elevate the cost of capital, and weigh on net income and earnings per share.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $59.75 for PACS Group based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $7.2 billion, earnings will come to $461.5 million, and it would be trading on a PE ratio of 26.3x, assuming you use a discount rate of 7.5%.
- Given the current share price of $46.67, the analyst price target of $59.75 is 21.9% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on PACS Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.